Particle Formation by Crystallization

Herman J.M. Kramer
Intensified Reaction & Separation Systems
Process & Energy
Delft University of Technology

Leeghwaterstraat 39
2628 CB Delft
The Netherlands
H.J.M.Kramer@tudelft.nl

Acknowledgement

Process & Energy – Intensified Reaction & Separation Systems

Delft University of Technology

Crystallization

A. Crystallization: Phenomena, Process & Product Properties

- Introduction Crystallization
- Crystals as Product:
  - Crystal purity, Crystal Size Distribution, Crystal shape and crystal solid form
- Crystallization kinetics
  - Nucleation, Crystal Growth, Attrition
- Crystallization process
  - thermodynamics
  - process design
  - equipment
  - modelling optimization and control

B. Advanced crystallization topics

- Polymorphism
- Chiral crystallization

Literature

Basic references

- Industrial Crystallization, fundamentals and application, A. Lewis, M.S. Seckler, H.J.M. Kramer and G.M van Rosmalen, Cambrridge University press, 2015
- Handbook of Industrial Crystallization, A.S Myerson, 2002, Butterworth- Heinemann
- Crystallization, J.W. Mullin, 2001,Butterworth & Heinemann
- Crystallization, H.J.M. Kramer, G.M. van Rosmalen, In: *Encyclopedia of Separation Science*, Ed. I.D. Wilson, 2000, Vol. 1, page 64-84.

Crystallization

A separation unit operation



Crystalline product
99.99% pure



- ✓ High selectivity
- ✓ Mild conditions
- ✓ Low energy demand
- ✓ Particular product
- ✓ Slow process

Pro's & Con's of Crystallization

- High distribution coefficient K_A of compound to be crystallized
- Low distribution coefficient K_S of solvent and impurities
- High selectivity α
- Pure product in one process step

$$K_A = \frac{x_A^{cr}}{x_A *} \approx \frac{1}{x_A *} \quad \text{(very large)}$$

$$K_S = \frac{x_S^{cr}}{x_S *} \approx \frac{0}{x_S *} \quad \text{(very small)}$$

$$a = \frac{K_i}{K_S} \quad \text{(very large)}$$



99.9-100% pure

Pro's & Con's of Crystallization

- **Highly selective**
- Energy efficient
- Mild conditions
- No auxiliary phase
- Solid particulate product



- **Slurry handling**
- Solid/liquid separation
- Complex control
- Fundamental knowledge
- Product specific designs
- Slow process:
  - Growth rate ~ 10^{-8}-10^{-7} m/s

99.9-100% pure

Crystallization is more than a separation technique

- **Separation**
  - Table salt, soda, sugar
- **Purification**
  - Pharmaceuticals, caprolactam, parrafin, proteins
- **Concentration**
  - Beverages, waste water
- **Particulate Product Formation**
  - nano-scale (creams, magnetic tapes, catalysts, zeolites)
  - micro-scale (inhalers)
  - macro-scale (silicon wafers)
  - Pharmaceutical crystal form: organic salt, polymorphism, co-crystals
- **Analysis**
  - Proteins

integration of **separation** and **crystalline product formation**

Relevance of Crystallization

- About 70% of all products are solids
- After distillation the most important separation technology
- The most frequently used separation technology

  - Food - Sugar, cacao butter, iced beer, sweeteners
  - Pharmaceuticals - Aspirin, inhalers, antibiotics, enzymes, insuline
  - Salt & derivatives - Table salt, soda
  - Fine-chemicals - Pigments
  - Petrochemicals - Starting material for polymers
  - Electronics - Silicon wafers
  - Agriculture - Fertilizer
  - Waste treatment - Freeze-concentration, metal-recovery

The Crystalline Product

Table salt

- Crystal purity >99.9%
- Crystal size distribution



- Crystal shape: cubic
- Crystal stucture
  - Solvates
  - Polymorphs
  - Chiral crystals



Crystallization occurs at molecular level

Incorporation of single molecules into the crystal lattice



Arrangement of millions of molecules into crystal lattice
Interaction at surface with solvent and impurities



Crystallization is highly selective
One step crystallizations can result in 99.9% pure products

Molecular structure: the crystal unit cell



Adipic acid
Monoclinic (P21/c)
$a \neq b \neq c$, $\alpha = \beta = 90° \neq \gamma$



Aspartame
Tetragonal (P41)
$a = b \neq c$, $\alpha = \beta = \gamma = 90°$

What is a crystal?

A **crystal** is
a solid
in which its building units
(molecules, atoms, ions)
are packed in
regularly ordered,
repeated patterns
extending in all 3 dimensions




Product
• Purity
• Size distribution
• Shape
• Crystal form
Fundamentals (molecular interactions)
Equipment design
Crystallization
Phenomena
• Nucleation
• Growth
• Attrition
• Agglomeration
Process design
Process
• Creation of supersaturation
• Crystallization method
• Batch ⇔ continuous

$MgSO_4$ Crystallisation plant



Product ⇔ phenomena



Impurity effect on product quality

Product is dependent on process conditions



Stimulate agglomeration during process to enhance filterability

Gypsum - $CaSO_4.2H_2O$

Crystallization Process

Principle phenomena



- Primary nucleation
- Secondary nucleation
  - Attrition /breakage
- Growth
- Agglomeration

Other properties of crystal products

Type of polymorph

- Shape
- Color
- Solubility
- Stability

Chirality

- Bio activity



5-Methyl-2-[(2-nitrophenyl)amino]-3-thiophenecarbonitrile
JACS **122** (2000) 585

Solid Forms in Pharmaceutical Industry

Some bestselling small molecule drugs in 2009

Brand Name	Company	API	Sales [billions $]	**# solid phases**
Lipitor	Pfizer	Atorvastatin Calcium	12.5	**41**
Diovan	Novartis	Valsartan	6.0	**10**
Nexium	AstraZeneca	Esomeprazole magnesium	5.0	**4**

1998 Product withdrawal of Norvir (ritonavir). Dissolution failure of oral capsules as a result of the appearance of a thermodynamically **more stable form**.

2008 Recall of Neupro (transdermal rotigotine) patches. Crystallization of a **new polymorph** that resembled snowflake-like crystals.

2010 Recall of the popular blood thinner Coumadin (warfarin sodium 2-propanol solvate). Variation in the 2-propanol levels, which affect the **crystallinity** of warfarin sodium.

Crystallization as a molecular affinity separation

- A directed spontaneous self-assembly of a 3-dimensional array of atoms, molecules or ions
- Crystallization is more than a separation technique: integration of separation and product formation
- Product quality aspects
  - Purity, CSD, shape, crystal form
- Crystallization requires sold/liquid separation steps

Main product quality characteristics



Crystal form

Crystal form



Crystal form: Hydrates and solvates



Gypsum ($CaSO_4.2H_2O$)



Anhydrite ($CaSO_4$)

Crystal form: Polymorphism

L-Glutamic acid



α-form



β-form

Crystal form: Polymorphism

$CaCO_3$ - Calcite (lozenges) and vaterite (spheres)

Crystal Size Distribution

Crystal size versus particle size





Particle size is a broader term

Particle size definitions

name	*definition*
length	maximal length
sieve diameter	width of the minimum square aperture through which the particle will pass
volume diameter	diameter of a sphere having the same volume as the crystal
surface diameter	diameter of a sphere having the same surface area as the crystal
projected area diameter	diameter of a sphere having the same projected area as the crystal viewed from a fixed direction

- Each method for size measurement captures a specific feature of particle size
- Do not compare sizes measured by distinct methods **!**

Particle size: Sieving





Aperture

Particle size distributions

Mass density distribution

Size range [μm]	Mass [g]
0 - 40	0.1
40 - 100	2.9
100 - 200	19.2
200 - 400	48.0
400 - 600	19.2
600 - 1000	9.6
1000 - 2000	1.0



<L>=362μm

Crystal Shape

Crystal shape









Crystal shape



crystal form (equilibrium shape)

nucleation
growth
agglomeration

supersaturation
impurities
solvent
temperature

Crystal morphology

- Morphology is determined by the slowest growing faces



Crystal shape: supersaturation effect



Lysozyme

Crystal shape

Thermal roughening



Temperature (S=1)

Kinetic roughening



Supersaturation (constant T)

Crystal shape: solvent effect

RDX crystal morphology from different solvents









Solvent can have a distinct effect on the crystal shape

Crystal shape: impurity effect

NaCl crystals



Table salt



grown in the presence of $Fe(CN)^{4-}_6$

Crystal shape: crystallizer



NaCl from a fluid bed crystallizer



NaCl from an Oslo crystallizer



NaCl grown in a rotating flow



NaCl grown under high supersation

Crystal Purity

Product purity

- Impurity incorporation in crystal lattice
- Inclusion of mother liquor
  - due to impurity and growth
  - due to attrition / secondary nucleation
- Impure product due to agglomeration
- Adhering mother liquor









Crystallization kinetics

- **Solubility, supersaturation and phase diagrams**

- **Nucleation** (formation of a new crystalline phase)
  - Primary nucleation
  - Secondary nucleation
- **Crystal growth** (mass deposition on existing crystals)
  - Mass transfer
  - Integration of solute molecules in crystal lattice
- **Agglomeration**
  - Collision
  - Cementation
  - Rupture

Solubility, supersaturation and Phase diagrams

Eutectic system, constant P



Lever-rule:

$$\text{Suspension density} = \frac{LZ}{LC}$$

Solubility ideal system:

Enthalpy of dissolution of B

$$x^* = \exp\left(-\frac{\Delta H}{R}\left(\frac{1}{T} - \frac{1}{T_m}\right)\right)$$

Mole fraction of B

Melting temperature Of pure B

Be careful solubility not dependent on the properties of the solvent. Not realistic!!!
! However the temperature dependence is.

Solubility, supersaturation and Phase diagrams

Eutectic system, constant P



Lever-rule:

$$\text{Suspension density} = \frac{LZ}{LC}$$

Definition supersaturation

$$\Delta\mu = \mu_L - \mu_S$$

$$\mu_S = \mu_S^{eq} = \mu_L^{eq} = \mu_L{}^* + kT \ln a_{eq}$$

$$\mu_L = \mu_L{}^* + kT \ln a$$

$$\Delta\mu = kT \ln \frac{a}{a_{eq}}$$

Supersaturation

$$\Delta\mu = kT \ln \frac{a}{a_{eq}}$$

$$\ln \frac{a}{a_{eq}} \approx \ln \frac{x}{x_{eq}} \approx \ln \frac{c}{c_{eq}} \approx \frac{c - c_{eq}}{c_{eq}} = \sigma$$

Ideal system
dilute system
low supersaturation

Dilute system

$1 < C/C_{eq} < 1.1$

Relative supersaturation

Methods to generate supersaturation

- See handbooks
- Important for the design of the crystallization process

How to measure solubility?

Temperature control



Stirrer



Suspension

- Establish an equilibrium in a stirred suspension at a given T,P between the solid and liquid phase
- Filter solution of crystals to isolate liquid
- Analyse the liquid phase to measure concentration at given T,P by evaporating the solvent or by analytical techniques

Alternative technique
Measure saturation temperature



Suspension
(Low T)

Clear solution
(high T)

Clear point:

The temperature at which a suspension becomes a clear solution during heating with a certain rate

Clear & Cloud Point Measurements



1440 min = 1 day

Crystallization kinetics

Primary nucleation



Crystallization kinetics

Primary Nucleation

- Homogeneous Nucleation (HON)
- Heterogeneous Nucleation (HEN)



spherical cluster in solution



cap-shaped cluster on a substrate

- **Primary nucleation is the process of random generation of nanoscopically small formations of a new phase that have the ability for irreversible growth to macroscopically large sizes.**
- **Primary nucleation is primarily driven by the level of supersaturation and conditions that facilitate the formation of a surface**

Primary nucleation

Nucleation model of Szilard: nucleation is a series of bimolecular "reactions" between molecules (monomers) and clusters.

$$1 \rightleftharpoons 2 \rightleftharpoons 3 \rightleftharpoons \ldots \rightleftharpoons n^*-1 \underset{g_n}{\overset{f_{n-1}}{\rightleftharpoons}} n^* \underset{g_{n+1}}{\overset{f_n}{\rightleftharpoons}} n^*+1 \rightleftharpoons \ldots$$



f_n – attachment frequency of monomers to n-sized cluster
g_n – detachment frequency of monomers to n-sized cluster

Nucleation work for HON

1. Creation of **volume**, ΔG_V
2. Creation of **surface**, ΔG_S
3. To form a cluster with n molecules, $W(n) = \Delta G_V + \Delta G_S$

$$W^* = \frac{16\pi v^2}{3k^2T^2} \frac{\gamma^3}{\ln^2 S}$$

Interfacial energy γ
and
supersaturation ratio S



$$J = A\exp\left(-\frac{W^*}{kT}\right) = A\exp\left(-\frac{16\pi v^2\gamma^3}{3k^3T^3\ln^2 S}\right)$$

Homogeneous and heterogeneous nucleation

Heterogeneous particles (dust particles, impurities, …) are always present

These particles affect the γ while also A is strongly different



Homogeneous

$A_{HON} = 10^{30}\text{-}10^{35}$

γ

$A_{HON} > A_{HEN}$

$\gamma > \gamma_{ef}$



Heterogeneous

$A_{HEN} = 10^{15}\text{-}10^{25}$

$\gamma_{ef} = \Psi\gamma$

with $0<\Psi<1$

At high S
Homogeneous nucleation dominant

At lower S
Heterogeneous nucleation dominant

Primary nucleation rate

The number of crystals created per unit of volume and time

J in units [$m^{-3}s^{-1}$]

Arrhenius type reaction

with energy barrier W^*



$$J = A\exp\left(-\frac{W^*}{kT}\right) = A\exp\left(-\frac{16\pi\, v^2\gamma^3}{3k^3T^3\ln^2 S}\right)$$

Highly non-linear behavior towards S and γ

Secondary nucleation



- Takes place in the presence of larger crystals (parent crystals)
- Stages:
  - generation of attrition fragments
  - removal of fragments from parent crystal
  - survival and growth of the fragments
- Is affected by hydrodynamics, design of equipment and the supersaturation and particle properties

Secondary nucleation rate: power law

$$B_0 = k_N G_L^i N^h M_T^j$$

or

$$B_0 = k_N^1 \sigma^b \overline{P}_{sp}{}^k M_T^j$$

B_0	=	Secondary nucleation rate [# m^{-3} s^{-1}]
G_L	=	Crystal growth rate (m/s), $G_L = k_g \sigma^b$
N	=	Impeller rotational speed [rpm]
M_T	=	Total mass of crystals per unit volume
σ	=	relative supersaturation σ (-)
P_{sp}	=	specific power input $P_{sp} \sim N^3$

k_N and $k_N{}^1$ are constants related to crystallizer geometry (impeller type, number of blades, scale of operation)

$1 < b < 3$; $0.6 < k < 0.7$; $j = 1$ or 2

Nucleation & growth in a batch process



Crystallization Characteristics

Clear point - Upon heating there is a temperature that a suspension turns into a clear solution

Cloud point - Upon cooling a solution there is a temperature that crystals will be detected

Metastable Zone Width - The difference between the saturation temperature (Clear point) and cloud point is the





Isonicotinamide in Ethanol: Metastable zone width



Why is there a difference between clear and cloud point?

Intermezzo

Non-Photochemical Laser Induced Nucleation (NPLIN)





NPLIN: Used to study the fundamental of primary nucleation
Facilitate primary nucleation at mild (low supersaturaton) conditions

Crystal growth: Smooth or rough surface

Smooth or layer growth

- growth units attach to kinks sites in the steps
- steps propagate along the crystal surface and form growth layers
- two step sources generate steps:
  - Birth and Spread growth mechanism
  - Spiral growth mechanism



Rough growth

- growth units attach anywhere to the rough crystal surface
  - Rough growth mechanism



The growth units are incorporated in an existing crystal lattice

Polymorphism

Dutch painter **Escher**

Fish form I

Fish form II

Crystal form



Polymorphism: product quality

The ability of a chemical compound to crystallize into different crystalline compounds



Polymorphism

- The number of forms known for a given compound is proportional to the time and money spent in research on that compound (McCrone, 1965)
  - Currently not true anymore – although now and then a new polymorph pops up
  - Succesfull research strategies have been developed to search for polymorphs

Record: 17 polymorphs

J.A. Pesti, R.A. Chorvat, G.F. Huhn, Chem. Innovations 2002, Oct. 28

Polymorphism: L-histidine

α-form
Orthorhombic
(P21 21 21)
a≠b≠c, α=β=γ=90°



β-form
monoclinic
(P21)
a≠b≠c, α=β=90°≠γ

Polymorphism: Ritonavir

- The HIV-1 and HIV-2 protease inhibitor Ritonavir



- In 1996 Ritonavir was introduced on the market

- In 1998 a **new, more stable form** appeared
- The new polymorph had a 4 times **lower solubility**
- This affected the **bioavailability** of the pharmaceutical
- The company Abbott withdrew Ritonavir from the market

- 1 year of research effort enabled the production of the old less stable polymorph again.

- **Costs**: 100 of millions of dollars

Thermodynamic stability: solubility





The transition temperature is independent from the solvent

Kinetics in cooling crystallization



Thermodynamics: Above Tt **I** is obtained, below Tt **II** is obtained, **but** …

Kinetics in cooling crystallization

Metastable zone widths



Kinetics in cooling crystallization



Kinetics in cooling crystallisation



Solvent mediated polymorph transformation: L-glutamic acid

Supersaturation

Supersaturation





Nucleation & crystal growth

Nucleation & crystal growth

Unstable Polymorph α

Solvent mediated polymorph **transformation**

Stable Polymorph β

Solvent mediated polymorph transformation: L-glutamic acid & Raman spectroscopy



Raman can detect polymorphic fraction in crystal phase of suspension

Control & optimization of polymorph crystallization



Large effect of temperature on transformation process

Kinetics in cooling crystallization

Metastable zone widths



Concomitant polymorphism



Calcite and vaterite ($CaCO_3$)



1,1-dicyano-4-(4-dimethylaminophenyl)-1,3-butadiene



Kinetics in cooling crystallization: oiling out



crystallization usually starts in the solute rich phase

Roger Davey, Chem. Comm. 2003

Anti-solvent crystallization

- Why?
  - Thermally instable API
  - Removal from remaining solution after cooling crystallization
- Solubility is variable
- Be aware of local conditions
- Many process configurations
- Wide variety of particle size distributions and polymorphs



Ascorbic acid from EtOH/CO_2



Acetaminophen from EtOH/CO_2

Kinetics in antisolvent crystallization





- Slow addition
- mild conditions
- less chance for unwanted polymorph

Kinetics in antisolvent crystallization





- Extreme supersaturations
- Concomitant polymorphism

Polymorphism: Ritonavir

- The HIV-1 and HIV-2 protease inhibitor Ritonavir



- In 1996 Ritonavir was introduced on the market

- In 1998 a **new, more stable form** appeared
- The new polymorph had a 4 times **lower solubility**
- This affected the **bioavailability** of the pharmaceutical
- The company Abbott withdrew Ritonavir from the market

- 1 year of research effort enabled the production of the old less stable polymorph again.

- **Costs**: 100 of millions of dollars

Kinetics in antisolvent crystallization

How to obtain the metastable form I of Ritonavir?

1. **Crystallize** form I
   a. suspension form I seeds in anti-solvent
   b. fed-batch addition of solution to anti-solvent

2. **Inhibition of transition** I => II
   Choice of solvent mixture inhibits transition

   Ethyl-acetate/Heptane **2:1** >90% polymorph **II**
   Ethyl-acetate/Heptane **1:2** mostly polymorph **I**

Conclusions

- Polymorphism is the ability of a chemical compound to form different crystalline lattices
- polymorphs differ in their physical properties and is therefore an important issue in pharmaceutical industry
- The crystallization of polymorphs is a process of nucleation and growth of both polymorphs and the possible solvent mediated transition from a metastable form to a more stable form.
- Crystallization of polymorphs is a balance between thermodynamics and kinetics

References

- Joel Bernstein, Polymorphism in molecular crystals, Clarendon Press, Oxford, 2002
- T. Threlfall, Crystallisation of Polymorphs: Thermodynamic Insight into the Role of Solvent, *Organic Process Research Development* **4** (2000) 384-390
- J. Bernstein, J. Dunitz, Disappearing polymorphs, *Acc. Chem. Res.* **28** (1995) 193-200.
- S. Gracin, Å.C. Rasmuson, Polymorphism and crystallization of p-aminobenzoic acid, *Crystal growth design* **4**(5) (2004) 1013-1023.
- J. Bauer et al., Ritonavir: An extraordinary example of conformational polymorphism, *Pharmaceutical research* **18**(6) (2001) 859-866.
- T. Ono, J.H. ter Horst, P.J. Jansens, Quantitative Measurement of the Polymorphic Transformation of L-Glutamic Acid Using In-Situ Raman Spectroscopy, Crystal Growth Design 4(3) (2004) 465-469.
- C.S. Towler, R.J. Davey, R.W. Lancaster, C.J. Price, Impact of molecular speciation on crystal nucleation in polymorphic systems: the conundrum of glycine and molecular "self poisioning", *J. Am. Chem. Soc.* **126** (2004) 13347-13353.

Chiral separation



Chirality

"I call any geometrical figure, or group of points, chiral, and say it has chirality, if its image in a plane mirror, ideally realised, cannot be brought to coincide with itself."

Lord Kelvin.

Baltimore Lectures on Molecular Dynamics and the Wave Theory of Light, 1904.

Enantiomers

Enantiomers are stereoisomer pairs in a mirror-image relationship.



Enantiomer pairs possess *identical physical properties*, but their *biological activities* *and effects can be markedly different*.

Amino acids

L-leucine
L-phenylalanine
L-tyrosine
L-tryptophan
All taste *bitter*.

D-leucine
D-phenylalanine
D-tyrosine
D-tryptophan
All taste *sweet*.

Aspartames



sweet



bitter

Thalidomide

In the 1960s, thalidomide was administered as a mixture of two enantiomeric forms:-



R-thalidomide
mild sedative



S-thalidomide
Causes birth defects

Chiral compounds

Racemic compound

enantiopure compound



Escher

Crystallization from a racemic mixture

Racemic compound

conglomerate

Escher

Crystallization from a racemic mixture

- **Racemic crystals** (92%).
  - Enantiomer pairs incorporated stoichiometrically into the unit cell.
  - Resolvable only by chemical intervention.
- **Conglomerates** (8%).
  - Mechanical mixtures of homochiral crystals of the two enantiomer forms.
  - Resolvable physically by crystallization methods.
- **Pseudoracemates** (very few).
  - Crystallize as solid solutions.
  - Require chemical intervention for resolution.

Solubility



If the solubility is low, the saturation temperature is high

Clear & Cloud Point Measurements



Clear Point & Solubility



Chiral compounds

Binary phase diagram



Chiral Compounds: Asparagine in Water

Ternary phase diagram screening







Conglomerate

Chiral Compounds: Ibuprofen in Hexane

Ternary phase diagram screening







Racemic compound

Chiral Compounds: Atenolol in Ethanol

Ternary phase diagram screening







Solid solution

Chiral Compounds

Ternary phase diagram screening

Racemic Compound, Conglomerate or Solid Solution?

- Saturation temperature measurements can be used to identify the kind of solid state of a chiral pharmaceutical at solution crystallization conditions
- The ternary phase diagram is obtained as a bonus

S. Sukanya, J.H. ter Horst,
Racemic Compound, Conglomerate, or Solid Solution: Phase Diagram Screening of Chiral Compounds,
Crystal Growth Design **10**(4) (2010) 1808-1812.

Phase diagram



Racemic crystals



Conglomerate

S. Srisanga, J.H. ter Horst, *Crystal growth design*, 2010

Resolution of Conglomerates - Methods available

1. Preferential crystallization
2. Crystallization of diastereomers
3. The grinding method: Combining a racemization reaction with suspension grinding

1. Preferential crystallization - principle



1. Preferential crystallization - principle

Add seeds
with excess S:

Only R crystals dissolve



1. Preferential crystallization - principle

Grow S crystals,

Remove S crystals



1. Preferential crystallization - principle

Add seeds
with excess R:

Only S crystals dissolve



1. Preferential crystallization - principle

Grow R crystals,

Remove R crystals



1. Preferential crystallization - principle

Take care in avoiding Crystallization of the Other enaniomer: Difficult!



2. Resolution of racemic crystal systems.

A single-enantiomer *resolving agent* can be used to form a pair of products in a *diastereomeric* relationship.

Example: racemic acid **(±)-A^-H^+** and resolving base **(+)-B**:

(±)-A^-H^+ + (+)-B → [(+)-A^-.(+)-BH^+] + [(-)-A^-.(+)-BH^+]

'p'-salt 'n'-salt

Compounds in diastereomeric relationships often exhibit significantly different physical properties, unlike enantiomer pairs.

Selection of resolving agent is a *trial-and-error* exercise.

2. Resolution of racemic crystal systems.

Model system



$$R = CH_3,\ C_2H_5,\ OH$$

2. Resolution of racemic crystal systems



2. Resolution of racemic crystal systems



3. The grinding method

Combining a racemization reaction and suspension grinding



W.L. Noorduin et al., *J. Am. Chem. Soc.* 130 (2008) 1158.

Chiral separation

- A conglomerate system can be separated using preferential crystallization

- A racemic compound can be separated by finding a suited resolving agent forming diastereomeric salts
- This pair of products can have distinct physical properties such as solubilities exploitable for chiral separation through crystallization

- The newly proposed grinding method combines a racemization reaction and grinding